Filed on behalf of: Par Pharmaceutical, Inc.

Entered: September 25, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.

Petitioner

v.

NOVARTIS AG
Patent Owner

G IDD 201 (01 450

Case IPR2016-01479 U.S. Patent No. 9,006,224

Before LORA M. GREEN, CHRISTOPHER L. CRUMBLEY, and ROBERT A. POLLOCK, *Administrative Patent Judges*.

PETITIONER'S REQUEST FOR ORAL ARGUMENT



Case IPR2016-01479 U.S. Patent No. 9,006,224

Pursuant to 37 C.F.R. § 42.70, the Board's Scheduling Order dated February 15, 2017 (Paper 9), Petitioner Par Pharmaceutical, Inc. ("Petitioner") respectfully requests oral argument on issues related to the patentability of claims 1-3 of U.S. Patent No. 9,006,224 ("'224 patent") on the instituted grounds set forth in the Board's Decision (Paper 8) and on any issues specified in any motions to exclude, motions for observation regarding cross-examination of reply witnesses, or any other pending motions filed by the parties. The Board has previously scheduled the oral argument for November 1, 2017. (Paper 9.)

Petitioner respectfully request that the Board allow Petitioner and Patent

Owner 45 minutes each to present their arguments, including any time reserved for rebuttal arguments.

Petitioner respectfully requests that the hearing be held in Room A, in order to accommodate the law firm representing the Petitioner, the law firm representing Patent Owner, as well as client representatives who may wish to attend. Petitioner requests permission to use a computer, projector, and screen to display demonstratives and exhibits. Petitioner also requests that the attorneys at



¹ There are also two joinder motions and petitions pending before the Board in IPR2017-01063 and IPR2017-01078. Petitioner anticipates that the petitioners and client representatives from these two petitions will also attend the oral argument.

Case IPR2016-01479 U.S. Patent No. 9,006,224

Petitioner's counsel table be allowed to use computers.

Respectfully submitted,

Dated: September 25, 2017 By: /Daniel G. Brown/

Daniel G. Brown (Reg. No. 54,005) daniel.brown@lw.com Latham & Watkins LLP 885 Third Avenue New York, NY 10022-4834 212.906.1200; 212.751.4864 (Fax)

Counsel for Petitioner Par Pharmaceutical, Inc.



CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 25th day of September, 2017, a copy of **Petitioner's Request for Oral Argument** was served by electronic mail on Patent Owner's lead and backup counsel at the following email addresses:

Nicholas N. Kallas (Reg. No. 31,530) Raymond R. Mandra (Reg. No. 34,382) Charlotte Jacobsen (*pro hac vice*) Fitzpatrick, Cella, Harper & Scinto 1290 Avenue of the Americas New York, NY 10104-3800 ZortressAfinitorIPR@fchs.com

By: /Daniel G. Brown/

Daniel G. Brown (Reg. No. 54,005) daniel.brown@lw.com Latham & Watkins LLP 885 Third Avenue New York, NY 10022-4834 212.906.1200; 212.751.4864 (Fax)

Counsel for Petitioner Par Pharmaceutical, Inc.

